Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Stopped Terminated due to loss of funding
Conditions
- Advanced Pleural Malignant Mesothelioma
- HLA-A*0201 Positive Cells Present
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Pleural Malignant Mesothelioma
- Stage III Non-Small Cell Lung Cancer AJCC v7
- Stage III Pleural Malignant Mesothelioma AJCC v7
- Stage IIIA Non-Small Cell Lung Cancer AJCC v7
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Stage IV Pleural Malignant Mesothelioma AJCC v7
- WT1 Positive
Interventions
- BIOLOGICAL: Aldesleukin
- BIOLOGICAL: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes
- DRUG: Cyclophosphamide
- OTHER: Laboratory Biomarker Analysis
- PROCEDURE: Therapeutic Conventional Surgery
Sponsor
Fred Hutchinson Cancer Center
Collaborators